Drugs / H7N3 pLAIV
last change Feb 2019 re-read 2 minutes ago

H7N3 pLAIV

Vaccine

Developed for
influenza
Investigated by
National Institute of Allergy and Infectious Diseases (NIAID)

Trials 1 · a red edge is where a trial was stopped

201820192020202120222023202420252026
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1 NCT03581903 Sep 2017 → Sep 2018 influenza National Institute of Allergy and Infectious Diseases (NIAID) Completed No outcome recorded

Evidence & citations 3 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as H7N3 pLAIV ClinicalTrials.gov intervention name — accepted as the source's own label NCT03581903
Modality Vaccine “live attenuated A/H7N3 influenza virus vaccineNCT03581903
Route Intranasal “administered intranasally by an Accuspray device” NCT03581903